Thomas Lincoln to Opioid-Related Disorders
This is a "connection" page, showing publications Thomas Lincoln has written about Opioid-Related Disorders.
Connection Strength
0.676
-
Lincoln T, Johnson BD, McCarthy P, Alexander E. Extended-release naltrexone for opioid use disorder started during or following incarceration. J Subst Abuse Treat. 2018 02; 85:97-100.
Score: 0.337
-
Evans EA, Stopka TJ, Pivovarova E, Murphy SM, Taxman FS, Ferguson WJ, Bernson D, Santelices C, McCollister KE, Hoskinson R, Lincoln T, Friedmann PD. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). J Subst Abuse Treat. 2021 09; 128:108275.
Score: 0.109
-
Springer SA, Di Paola A, Azar MM, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial. J Acquir Immune Defic Syndr. 2018 05 01; 78(1):43-53.
Score: 0.091
-
Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp Clin Trials. 2014 Nov; 39(2):256-68.
Score: 0.071
-
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. J Subst Abuse Treat. 2014 Jul; 47(1):35-40.
Score: 0.068